Giant Cell Arteritis Pipeline 2025: Key Clinical Developments by 80+ Global Innovators - DelveInsight | Highlighting Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Eli Lilly, Janssen Biotech, and Dr

DelveInsight's, "Giant-Cell Arteritis - Pipeline Insight, 2025," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Giant-Cell Arteritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Giant Cell Arteritis (GCA) becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the demand for safer and more effective treatments continues to grow. DelveInsight reports that more than six pharmaceutical and biotech companies are actively advancing over six therapeutic candidates targeting GCA. These candidates are in various stages of preclinical and clinical development, reflecting significant innovation and dedication to addressing this critical public health challenge.

DelveInsight's "Giant Cell Arteritis Pipeline Insight 2025" provides a comprehensive analysis of the current R&D landscape. The report examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and strategic initiatives by leading companies. It is a valuable resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving GCA therapeutics market and the innovations shaping its future.

Explore the Cutting-Edge Landscape of Giant Cell Arteritis Drug Development [https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Takeaways from the Giant Cell Arteritis Pipeline Report

*
DelveInsight's Giant Cell Arteritis (GCA) pipeline report highlights a dynamic landscape, with over six active companies developing more than six therapeutic candidates for GCA treatment.

*
In July 2025, Novartis' Cosentyx (secukinumab) did not meet its primary endpoint in the Phase III GCAptAIN trial, failing to show a significant improvement in sustained remission at 52 weeks compared to placebo. Although there were reductions in steroid use, these differences were not statistically significant.

*
In contrast, in April 2025, AbbVie's Rinvoq (upadacitinib) became the first oral JAK inhibitor approved by the FDA for adult GCA patients. Approval was based on the Phase III SELECTGCA trial, where 46.4% of patients receiving 15mg daily with a steroid taper achieved sustained remission between weeks 12 and 52, compared to 29% in the placebo group (p=0.002).

*
Key companies-including Novartis, AbbVie, XOMA, Kiniksa, Eli Lilly, Janssen Biotech, Dr. Reddy's Laboratories, and others-are actively developing new therapies to enhance the GCA treatment landscape. Promising pipeline candidates in various stages of development include Secukinumab, Upadacitinib, and additional therapies.

Giant Cell Arteritis Overview:

Giant cell arteritis (GCA) is the most common type of vasculitis in individuals over 50, characterized by inflammation of medium and large arteries. This inflammation thickens and damages vessel walls, reducing blood flow. The temporal and other cranial arteries are often affected-a form known as cranial GCA-but the aorta and other large vessels can also be involved, referred to as large-vessel GCA, which may present with distinct symptoms. Without timely diagnosis and treatment, GCA can cause serious complications, including sudden and permanent vision loss.

When cranial arteries are involved, patients may experience unilateral or occipital headaches, jaw pain while chewing (jaw claudication), scalp tenderness, arm discomfort, visual disturbances such as double vision, and noticeable, tender swelling of the temporal artery. Systemic symptoms, more common in large-vessel GCA, can include fever, weight loss, loss of appetite, and polymyalgia. While the exact cause of GCA is unknown, it is believed to result from the immune system attacking the body's own blood vessels.

GCA is closely associated with polymyalgia rheumatica (PMR): approximately 40-60% of GCA patients also have PMR, and 15-20% of PMR patients may develop GCA. Treatment typically involves corticosteroids to relieve symptoms and prevent recurrence, often combined with immunosuppressive therapies to regulate the immune response.

Download the Giant Cell Arteritis sample report to know in detail about the Giant Cell Arteritis treatment market [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Giant Cell Arteritis Pipeline Analysis

The Giant Cell Arteritis pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Giant Cell Arteritis Market.

*
Categorizes Giant Cell Arteritis therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Giant Cell Arteritis drugs under development based on:

*
Stage of development

*
Giant Cell Arteritis Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Giant Cell Arteritis Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Giant Cell Arteritis Licensing agreements

*
Funding and investment activities supporting future Giant Cell Arteritis market advancement.

Unlock key insights into emerging Giant Cell Arteritis therapies and market strategies here: https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Giant Cell Arteritis Emerging Drugs

*
Secukinumab: Novartis

Secukinumab is a fully human monoclonal antibody (IgG1/) that specifically targets interleukin-17A (IL-17A), a key proinflammatory cytokine implicated in chronic immune-mediated inflammatory disorders such as plaque psoriasis. By inhibiting IL-17A, secukinumab helps reduce inflammation associated with these conditions.

The therapy was initially approved in Japan in December 2014, followed by approval from the European Commission on January 15, 2015, and the U.S. FDA on January 21, 2015. Secukinumab is currently approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is now undergoing Phase III clinical trials to assess its potential in treating Giant Cell Arteritis (GCA).

*
Upadacitinib: AbbVie

Upadacitinib is an oral, selective Janus kinase 1 (JAK1) inhibitor approved for treating several inflammatory disorders, including moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, particularly in patients who have not responded adequately to prior treatments. The FDA approved upadacitinib in August 2019 for multiple indications, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis, while the European Commission followed with approval in December 2019. Marketed as RINVOQ, it is currently being evaluated in Phase III clinical trials for its potential use in Giant Cell Arteritis (GCA).

Giant Cell Arteritis Pipeline Therapeutic Assessment

Giant Cell Arteritis Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Giant Cell Arteritis By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Giant Cell Arteritis Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Giant Cell Arteritis Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Giant Cell Arteritis therapies and key Giant Cell Arteritis companies [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Giant Cell Arteritis Current Treatment Patterns

4. Giant Cell Arteritis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Giant Cell Arteritis Late-Stage Products (Phase-III)

7. Giant Cell Arteritis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Giant Cell Arteritis Discontinued Products

13. Giant Cell Arteritis Product Profiles

14. Giant Cell Arteritis Key Companies

15. Giant Cell Arteritis Key Products

16. Dormant and Discontinued Products

17. Giant Cell Arteritis Unmet Needs

18. Giant Cell Arteritis Future Perspectives

19. Giant Cell Arteritis Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Giant Cell Arteritis pipeline reports offerings [https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=giant-cell-arteritis-pipeline-2025-key-clinical-developments-by-80-global-innovators-delveinsight-highlighting-novartis-abbvie-xoma-kiniksa-pharmaceuticals-eli-lilly-janssen-biotech-and-dr]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.